Bioindicadores neotropicais de ecotoxicidade e risco ambiental de fármacos de interesse para aquicultura

The aims of this research were to evaluate the acute toxicity (LC/EC50) and the environmental risk of toltrazuril (TOL) and florfenicol (FFC) for plant Lemna minor, snail Pomacea canalicuta, fish Piaractus mesopotamicus and Hyphessobrycon eques and the microcrustacean Daphnia magna. The organisms were acclimated in room bioassay with controlled temperature according to standard to each one. They were exposed at nominal concentrations in static system. For environmental risk (RQ) was used the estimated environmental concentration (EEC) that is the dosage indicate to treatment and the lethal or effective concentration (LC/CE50) from each drug in acute exposure. FFC showed LC50;7d of 97.03 mg L-1 for L. minor; >100.0 mg L-1 for P. mesopotamicus and H. eques and EC50;48h > 100.0 mg L-1 for P. canaliculata and D. magna, and it was classified low risk (RQ = 0.01) for all bioindicators. TOL howed LC50;7d >100.0 mg L-1 for L. minor, 3.72 mg L-1 for P. mesopotamicus; 6.22 mg L-1 for H. eques and CE50;48h of 7.59 mg L-1 for P. canaliculata and 18.57 mg L-1 for D. magna, and it was classified low risk (RQ = 0.01) for L. minor and high risk for P. mesopotamicus (RQ = 2.68), H. eques (RQ = 6.22), P. canaliculata (RQ = 1.31) and D. magna (RQ = 0.53). Lemna minor was the bioindicator indicating of FFC toxicity and H. eques, bioindicator of the TOL. FFC is safety however and the use of TOL necessaries cautions to treat the wastewater before discard on the environment.

Development and validation of UV spectrophotometric method for orbifloxacin assay and dissolution studies

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Desenvolvimento de dispersões sólidas e nanopartículas poliméricas mucoadesivas de Zidovudina e avaliação da interação biológica com a mucosa intestinal

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Farmacocinética do Benznidazol administrado em coelhos na forma de comprimidos de liberação imediata e comprimidos de liberação prolongada

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Sistemas precursores de cristais líquidos mucoadesivos para administração bucal de curcumina no tratamento do câncer bucal

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Síntese, caracterização e avaliação da atividade biológica de metalofármacos de sulindaco com íons lantanídeos (III) no estado sólido

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Perfil tóxico-farmacológico da administração da doxorrubicina em cães com tumor venéreo transmissível

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Efeito de scaffolds de nanofibras incorporados com antibióticos sobre biofilmes formados por bactérias presentes nos canais radiculares

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Medicamentos inadequados para idosos na estratégia da saúde da família

The ageing process can change the pharmacodynamics and pharmacokinetics parameters. Therefore, some medications are considered potentially inappropriate (PIM) for the elderly people, since they can increase the likelihood of occurrence of adverse drug events. The objectives are to estimate the frequency of use of PIM in the elderly people, with potentially hazardous drug interactions (PHDI) and to evaluate the impact of pharmaceutical intervention (PI) for the prescription of safer therapeutic alternatives. A cross-sectional study was performed in a Health Family Strategy (region of Araraquara, SP), between January and February/2012. The medical records of patients aged ≥60 years, that use at least one drug, were consulted for identification of PIM, according to the Beers criteria. The MPI identified were classified considering the Anatomical Therapeutic Chemical Classification System (ATC) and the essentiality of the drug (safety, effectiveness, quality and cost parameters) The inclusion criteria were met by 358 elderly, being that 93 of them (26%) had taken at least one PIM. Of the 114 different drugs prescribed for elderly, ten were classified as PIM, of which four of them act on the central nervous system, four on cardiovascular system and two on the digestive tract. Seven MPI are essential medicines, belonging to national list of essential drugs (RENAME-2010). Fourteen drug interactions were identified, of which two are PHDI (fluoxetine/amitriptyline and digoxin/hydrochlorothiazide).After the PI, there was no change in medical prescriptions of patients with PIM use or with DI. Medical prescriptions of elderly attended in the Health Family Strategy show pharmacotherapeutic safety problems, of which may be responsible for health hazardous for this age group. Although the intervention carried out by letter had been ineffective for the adherence of doctors in prescribing safe alternatives, wide dissemination of the lists that contain PIM and PHDI is need, as well as the inclusion of safer equivalents in RENAME, in order to contribute for rational use of drugs.

Development and characterization of cefoxitin loaded D,L-PLA nanoparticles

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Assessment of the quality evaluation of compounded fluconazole capsules marketed in the region of Araraquara (SP, Brazil)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Estudo comparativo de cápsulas contendo amoxicilina obtidas de algumas farmácias magistrais

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Farmacocinética e farmacodinâmica de derivado ftalimídico planejado para o tratamento da anemia falciforme

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Síntese e avaliação farmacológica de pró-fármacos derivados do ácido micofenólico úteis na prevenção e no tratamento da rejeição de transplantes

Pós-graduação em Ciências Farmacêuticas - FCFAR

Injeção de colecalciferol in ovo e adição de alendronato de sódio na dieta hídrica para frangos de corte

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)